Taurolidine

Summary

Taurolidine (CHEMBL2105420) is an approved small-molecule antibacterial agent (ATC B05CA05); indicated across 5 conditions including central nervous system neoplasm and peritoneal neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05CA05
• Indications: 5 conditions
• Clinical trials: 11
• Chemistry: 284.4 Da · C7H16N4O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105420
Name	Taurolidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	29566
ChEBI	CHEBI:135173
ATC	B05CA05
Molecular formula	C7H16N4O4S2
Molecular weight	284.4
InChIKey	AJKIRUJIDFJUKJ-UHFFFAOYSA-N

SMILES: C1CS(=O)(=O)NCN1CN2CCS(=O)(=O)NC2

IUPAC name: 4-[(1,1-dioxo-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide

ChEBI definition: A member of the class of thiadiazinanes that is 1,2,4-thiadiazinane 1,1-dioxide substituted by a (1,1-dioxido-1,2,4-thiadiazinan-4-yl)methyl group at position 4. It is a broad-spectrum antiseptic used as lock therapy solution in patients with long term central venous catheters for the prevention of catheter related bloodstream infections.

Pharmacological roles (ChEBI): antibacterial agent, anti-inflammatory agent, antifungal agent, antiseptic drug, antineoplastic agent.

Also known as: (cyclo)-taurolidine, Cyclo-taurolidine, Taurolidina, Taurolidine, Taurolidine component of defencath, Taurolidine component of taurolock, W-3100M, TAUROLIDINE, taurolidine

Patent coverage: 1,024 distinct patent families (3,667 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Alpha-2B adrenergic receptor, Histamine H1 receptor, D(3) dopamine receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	5.34	AC50	4600	nM	CHEMBL_ACT_25212711

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158
peritoneal neoplasm	1	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	1	MONDO:0021092	MONDO:0002158
ovarian cancer	1	MONDO:0008170	MONDO:0008170

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
Not specified	4
PHASE4	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02009189	PHASE4	COMPLETED	Taurolidine Lock in Long Term Parenteral Nutrition
NCT02515201	PHASE4	UNKNOWN	Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children
NCT03539718	PHASE4	UNKNOWN	Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.
NCT00321165	PHASE3	COMPLETED	The AOT (Acridine Orange and Taurolidine) Trial
NCT02036255	PHASE3	COMPLETED	Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase
NCT00021034	PHASE1	COMPLETED	Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00022360	PHASE1	COMPLETED	Taurolidine in Treating Patients With Recurrent or Progressive Glioma
NCT06707480	Not specified	AVAILABLE	Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
NCT07585188	Not specified	NOT_YET_RECRUITING	Neonatal Catheter Lock for Infection Prevention
NCT00545831	Not specified	TERMINATED	Effect of Taurolidin on Prevention of Bloodstream Infection
NCT05576194	Not specified	COMPLETED	Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).